1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Cipla Ltd

Cipla Ltd

1,330.90
INR
+16.90
(+1.29%)
40.75EPS
35.67P/E
1.18TMarket Cap
Oct 27Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
126.7
140.29
165.59
174.69
182.5
198.31
207.13
235.48
268.06
278.48
315.21
336.14
343.08
338.61
Basic EPS, GAAP
17.29
14.71
16.93
12.52
17.53
18.97
19.19
29.82
31.2
34.72
51.05
65.29
48.03
41.08
Free Cash Flow per Basic Share
19.47
14.61
21.68
29.62
8.03
14.45
25.66
36.41
32.54
25.46
34.49
42.81
10.66
- -
Dividend per Share
2
2
2
2
2
3
7
- -
5
5
8.5
13
16
- -
Book Value per Share
125.17
132.73
143.35
155.92
176.73
186.33
195.51
227.25
258.32
290.01
330.78
386.24
426.25
- -
Tangible Book Value per Share
92.93
99.59
67.63
88.23
113.35
127.03
135.56
167.29
198.32
234.08
272.41
324.5
341.45
- -
Basic Weighted Avg Shares
803
803
803
804
805
805
806
806
807
807
807
808
808
807
Sales/Revenue/Turnover
101,734
112,645
132,990
140,449
146,873
159,710
166,949
189,885
216,234
224,732
254,466
271,454
277,117
273,413
Operating Margin (%)
20.15
14.77
13.07
11.7
12.84
12.74
12.64
17.12
16.51
17.88
21.1
22.63
17.49
14.65
Depreciation Expense
3,726
5,047
7,542
13,229
13,228
13,263
11,747
10,031
9,901
10,192
10,510
9,955
10,836
12,182
Net Income, GAAP
13,884
11,808
13,600
10,064
14,105
15,277
15,465
24,049
25,168
28,019
41,216
52,725
38,792
33,171
Effective Tax Rate (%)
24.65
24.18
19.2
14.71
14.98
27.39
28.98
27.01
26.73
29.79
27.12
22.43
25.92
25.79
Profit Margin (%)
13.65
10.48
10.23
7.17
9.6
9.57
9.26
12.66
11.64
12.47
16.2
19.42
14
12.13
Working Capital
30,884
37,964
10,652
54,309
69,819
86,551
73,130
86,180
98,143
121,653
141,956
178,046
171,334
- -
LT Debt
3,179
3,093
2,219
36,454
36,621
38,301
25,524
14,006
5,745
2,088
2,254
2,525
3,820
- -
Total Equity
100,999
109,892
118,663
129,819
145,816
153,443
160,573
185,856
211,174
237,135
268,023
312,893
345,202
- -
Return on Invested Capital (%)
14.54
10.62
9.58
6.02
7.01
7.12
7.66
12.11
11.63
11.28
14.39
16.22
9.93
- -
Return on Capital (%)
13.21
9.84
9.59
6.5
8.37
8.77
8.91
12.75
11.99
12.15
15.97
17.97
11.76
- -
Return on Common Equity (%)
14.56
11.4
12.27
8.37
10.54
10.45
10.05
14.11
12.85
12.66
16.45
18.21
11.82
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
2,318
- -
LT Borrowings
- -
1,175
- -
LT Finance Leases
- -
2,645
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
808
808
808
Market Capitalization
1,220,786
988,887
1,183,817

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
241,470
- -
Cash, Cash Equivalents & STI
- -
100,281
- -
Accounts Receivable, Net
- -
56,201
- -
Inventories
- -
65,967
- -
Total Current Liabilities
- -
70,136
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
2,318
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.34%
13.2%
10.33%
Free Cash Flow
11.59%
-9.55%
-75.1%
Net Income, GAAP
14.38%
12.92%
-26.43%
Sales/Revenue/Turnover
7.7%
7.96%
2.09%
Total Cash Common Dividend
- -
- -
23.11%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
66,249
69,612
69,616
65,977
271,454
2026
68,370
- -
69,630
64,643
277,117
2027
70,770
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
14.58
16.13
19.45
15.13
65.29
2026
16.07
- -
8.37
6.87
48.03
2027
9.77
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
13
2026
- -
- -
- -
- -
16
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Achin Gupta
Full Time Employees
47,496
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Cipla House Mumbai MA India 400013
IPO Date
Nov 3, 1994
Website
cipla.com
Similar Companies
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Upexi, Inc. (NASDAQ:UPXI)
Business
Cipla Limited Cipla Limited engages in the research, development, manufacturing, and marketing of a broad portfolio of pharmaceutical products and healthcare solutions worldwide. Founded in 1935 and headquartered in Mumbai, India, the company offers generics and branded generics; specialty medicines in respiratory, central nervous system, and critical care areas; consumer health products including Nicotex for smoking cessation, Cofsils for cough and throat relief, Ciphands sanitizers, and nutritional supplements like ActivKids; active pharmaceutical ingredients; respiratory devices such as inhalers, nebulizers, Ciphaler, Synchrobreathe, CipAir, and Spirofy spirometers; digital health tools like the Breathefree app; and therapies spanning respiratory diseases with brands like Foracort, Budecort, and Duolin; cardiology for hypertension and lipid management; urology with Urimax; anti-infectives including antibiotics and antimalarials; neuroscience for epilepsy, Parkinson's, and depression; oncology with nilotinib and lenalidomide; anti-retrovirals for HIV/AIDS; diabetology featuring Afrezza inhaled insulin and CipA1cDuo diagnostics; dermatology; and obesity treatments with GLP-1 agonists. Cipla Limited operates manufacturing facilities across India, the United States, South Africa, and other regions, serving over 80 countries with a focus on emerging markets including India, the US, and South Africa, and targets patients, healthcare professionals, and institutional customers through more than 4,000 partners in India alone. In recent developments, Cipla Limited acquired 100% of Inzpera Healthsciences Limited for approximately INR 110.65 crore in November 2025 to expand its pediatric pharmaceutical and wellness portfolio; completed a 20% stake acquisition in iCaltech Innovations for INR 5 crore in August 2025 to bolster respiratory diagnostics; and expanded its US manufacturing facility in Fall River, Massachusetts, by 83,000 square feet in August 2025 to enhance production of complex respiratory generics while receiving tax incentives and announcing new hiring.

Company News

Company News APIChatGPT

  • prnewswire.com

    Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

  • prnewswire.com

    Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy